Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - aTYR PHARMA INC | d87727dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 19, 2015
ATYR PHARMA, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-37378 | 20-3435077 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
3545 John Hopkins Court, Suite #250
San Diego, CA 92121
(Address of principal executive offices, including zip code)
(858) 731-8389
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 19, 2015, aTyr Pharma, Inc. (the “Company”) and David M. Weiner, M.D., the Company’s Chief Medical Officer, agreed upon a transition plan whereby Dr. Weiner will transition from his role as Chief Medical Officer to that of a clinical advisor to the Company supporting the Company’s execution of its clinical trials of Resolaris through the first quarter of 2016. The Company anticipates that this transition will be implemented within the next few weeks.
Item 7.01 Regulation FD Disclosure.
In connection with Dr. Weiner’s transition to an advisory role, the Company issued a press release on July 20, 2015. A copy of the press release is attached as Exhibit 99.1.
The information furnished pursuant to this Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liability of that section, nor shall such information be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press release dated July 20, 2015 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 20, 2015 | aTyr Pharma, Inc. | |||||
| By: | /S/ JOHN D. MENDLEIN | |||||
| John D. Mendlein, Ph.D. | ||||||
| Chief Executive Officer and Executive Chairman | ||||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press release dated July 20, 2015 | |